ReviewThe British journal of ophthalmology2021
COVID-19 and immunosuppression: a review of current clinical experiences and implications for ophthalmology patients taking immunosuppressive drugs.
Review in The British journal of ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 106 citations in OpenAlex.
- Current trends and geographical differences in therapeutic profile and outcomes of COVID-19 among pregnant women - a systematic review and meta-analysis.BMC pregnancy and childbirth · 2021Pooled it
- Lingering echoes of SARS-CoV-2: mechanistic insights and management of long COVID syndrome.Inflammopharmacology · 2026Review
- Oleuropein modulates anti-inflammatory activity of celecoxib and ketoprofen through cyclooxygenase pathway: in vivo, in silico and pharmacokinetics approaches.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Immune-mediated extraocular myositis in an adolescent following coronavirus disease 2019: A case report.The Journal of international medical research · 2025Article
- Exploring the association of social isolation and loneliness on the experience of COVID-19 infection and hospitalization in the Japanese population: the JACSIS study.Social psychiatry and psychiatric epidemiology · 2025Article
- Risk of COVID-19 infection and seizure exacerbation among patients with epilepsy during the peak of Omicron wave.Epilepsia open · 2024Article
- Harnessing immunity: Immunomodulatory therapies in COVID-19.World journal of virology · 2024Review
- Decoding Immuno-Competence: A Novel Analysis of Complete Blood Cell Count Data in COVID-19 Outcomes.Biomedicines · 2024Article
- Systematic review and meta-analysis of knowledge, attitudes, and practices regarding COVID-19 among chronic disease patients: A global perspective.Health science reports · 2024Article
- An Outbreak of Acute Hemorrhagic Conjunctivitis Caused by Coxsackievirus A24 in Eastern Uttar Pradesh, India 2023.Intervirology · 2024Article
- Evaluating chronic pain as a risk factor for COVID-19 complications among New York State Medicaid beneficiaries: a retrospective claims analysis.Pain medicine (Malden, Mass.) · 2023Article
- Outcome of COVID-19 in Egyptian living-donor kidney transplant recipients and relation to maintenance immunosuppressive drugs: a pilot study.Scientific reports · 2023Article
- Coronavirus disease 2019 in kidney transplant recipients: a systematic review and meta-analysis.Singapore medical journal · 2023Review
- Undiagnosed Behçet's Disease Complicated by Multiple Pseudoaneurysms and COVID-19 Infection.The International journal of angiology : official publication of the International College of Angiology, Inc · 2023Article
- COVID-19-related anxiety trajectories in children, young people and adults with rheumatic diseases.Rheumatology advances in practice · 2023Article
- The role of immune suppression in COVID-19 hospitalization: clinical and epidemiological trends over three years of SARS-CoV-2 epidemic.Frontiers in medicine · 2023Article
- Adverse Effects of COVID-19 Vaccination: Machine Learning and Statistical Approach to Identify and Classify Incidences of Morbidity and Postvaccination Reactogenicity.Healthcare (Basel, Switzerland) · 2022Article
- Antigenic escape is accelerated by the presence of immunocompromised hosts.Proceedings. Biological sciences · 2022Article
- COVID-19 outcomes in patients with Dermatomyositis: A registry-based cohort analysis.Seminars in arthritis and rheumatism · 2022Article
- Association between Immunosuppressive Drugs and Coronavirus Disease 2019 Outcomes in Patients with Noninfectious Uveitis in a Large US Claims Database.Ophthalmology · 2022Article
Corrections and comments
- Commented on by
Authors and funding
12 authors at 9 institutions in 7 countries.
Funding
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019 in Wuhan city, Hubei province, China. This is the third and largest coronavirus outbreak since the new millennium after SARS in 2002 and Middle East respiratory syndrome (MERS) in 2012. Over 3 million people have been infected and the COVID-19 has caused more than 217 000 deaths. A concern exists regarding the vulnerability of patients who have been treated with immunosuppressive drugs prior or during this pandemic. Would they be more susceptible to infection by the SARS-CoV-2 and how would their clinical course be altered by their immunosuppressed state? This is a question the wider medical fraternity-including ophthalmologists, rheumatologists, gastroenterologist and transplant physicians among others-must answer. The evidence from the SARS and MERS outbreak offer some degree of confidence that immunosuppression is largely safe in the current COVID-19 pandemic. Preliminary clinical experiences based on case reports, small series and observational studies show the morbidity and mortality rates in immunosuppressed patients may not differ largely from the general population. Overwhelmingly, current best practice guidelines worldwide recommended the continuation of immunosuppression treatment in patients who require them except for perhaps high-dose corticosteroid therapy and in patients with associated risk factors for severe COVID-19 disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.